

# A Facile Synthesis of Flumazenil Analogues

## Gianluigi Broggini,\*a Giorgio Molteni, b Alberto Terraneo and Gaetano Zecchi

<sup>a</sup> Università dell'Insubria, Dipartimento di Scienze Chimiche, Fisiche e Matematiche, via Lucini 3, 22100 Como, Italy
<sup>b</sup> Università di Milano, Dipartimento di Chimica Organica e Industriale, via Golgi 19, 20133 Milano, Italy

Received 2 August 1999; revised 30 September 1999; accepted 14 October 1999

Abstract: A number of 8-substituted 5-methyl[1,2,3]triazolo[1,5-a][1,4] benzodiazepin-6(4H)-ones (6) were synthesised in a concise and efficient way starting from isatoic anhydrides and exploiting an intramolecular azide cycloaddition. © 1999 Published by Elsevier Science Ltd. All rights reserved.

1,4-Benzodiazepines fused to a five-membered heterocycle occupy a prominent place among drugs for the treatment of CNS disturbances.<sup>1-5</sup> For instance, alprazolam 1 is a common anxiolytic agent,<sup>6</sup> while flumazenil 2 belongs to the family of cognition enhancers.<sup>7</sup>

Within our research into heterocyclic syntheses by means of intramolecular 1,3-dipolar cycloadditions of the azido group, <sup>8.9</sup> we have developed a facile entry to a series of 8-substituted 5-methyl-[1,2,3]triazolo[1,5-a][1,4]benzodiazepin-6(4H)-ones 6, the structure of which is closely related to that of flumazenil.

#### Results and Discussion

Our synthetic approach started from the reaction of 5-substitued isatoic anhydrides 3 with the commercially available methylpropargylamine (Scheme 1). The reaction was carried out in boiling dioxane in the case of 3a and in boiling DMF in the case of the less reactive substrates 3b-d, to give the anthranilamides 4 in 44-54% yield. These were subjected to diazotization and subsequent reaction of the intermediate diazonium salts with sodium azide. The expected azides 5 were not isolable as intramolecular cycloaddition onto the acetylenic bond occurred spontaneously in situ, and simple evaporation of the solvent led to the final targets 6. The overall yields of 41-55% in this cascade-type reaction sequence from 4 are preparatively useful. Further in order to widen the variety of the targets, the nitro derivate 6d was converted into the corresponding amino derivative 6e via catalytic hydrogenation.

### Scheme 1

The toxicological and pharmacological properties of the tricyclic compounds 6a-e are under evaluation.

#### **Experimental Section**

M.p. were determined on a Büchi apparatus and are uncorrected. IR Spectra were recorded on a FT-IR Perkin-Elmer 1725X spectrophotometer. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were taken using a Bruker 300 MHz apparatus; chemical shifts are given in ppm from SiMe<sub>4</sub>, with coupling constants in Hz. Mass spectra were determined with a VG-70EQ apparatus.

Compounds 3a,b were commercially available. Compounds  $3c^{10}$  and  $3d^{11}$  were prepared according to literature methods.

**2-Amino-***N***-methyl-***N***-(prop-2-ynyl)benzamide 4a.** *N***-**Methylpropargylamine (200 mg, 2.9 mmol) was added to a solution of **3a** (315 mg, 1.9 mmol) in dioxane (10 mL). The mixture was heated at reflux for 3 h, then poured in ice/water (50 mL), adjusted to pH 9 with 5% NaOH and extracted with Et<sub>2</sub>O. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The crude product was chromatographed on silica with chloroform/methanol 10:1 as eluent to give **4a** (195 mg, 54%). Oil; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.31 (1H, t, J 2.4), 3.09 (3H, s), 4.19 (2H, d, J 2.4), 4.40 (2H, br s, missing after deuteriation), 6.71 (1H, d, J 7.7), 6.73 (1H, dd, J 7.4, 7.7), 7.14-7.24 (2H, m); IR (nujol) 1620, 2120, 3280, 3350, 3450 cm<sup>-1</sup>; MS m/z 188 (M<sup>+</sup>); Anal. Calcd. for C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O: C, 70.19; H, 6.43; N, 14.88. Found: C, 70.3; H, 6.48; N, 15.01.

General procedure for preparation of anthranilamides 4b-d. N-Methylpropargylamine (3.6 mmol) was added to a solution of 3b-d (1.6 mmol) in DMF (8 mL). The mixture was heated at reflux for 3 h, then poured in ice/water (50 mL), adjusted to pH 9 with 5% NaOH and extracted with Et<sub>2</sub>O. The organic layer was dried

over  $Na_2SO_4$  and evaporated under reduced pressure. The crude product was chromatographed on silica with chloroform/methanol 10:1 as eluent for **b-c** and diethyl ether/light petroleum 10:1 for **c**, giving the pure products **4b-d**.

**4b**: (53%). Oil; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.32 (1H, t, *J* 2.3), 3.10 (3H, s), 4.19 (2H, d, *J* 2.3), 4.36 (2H, br s, missing after deuteriation), 6.64 (1H, d, *J* 8.6), 7.11 (1H, dd, *J* 2.4, 8.6), 7.16 (1H, d, *J* 2.4); IR (nujol) 1620, 2110, 3290, 3350, 3460 cm<sup>-1</sup>; MS m/z 222 (M<sup>+</sup>); Anal. Calcd. for C<sub>11</sub>H<sub>11</sub>ClN<sub>2</sub>O; C, 59.33; H, 4.98; N, 12.58. Found: C, 59.26; H, 5.14; N, 12.53.

**4c**: (50%). Oil; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.31 (1H, t, *J* 2.3), 3.10 (3H, s), 4.09 (4H, overlapping; after deuteriation: d, *J* 2.3), 6.66 (1H, dd, *J* 4.5, 9.2), 6.88-6.94 (2H, m); IR (nujol) 1625, 2120, 3295, 3350, 3450 cm<sup>-1</sup>; MS: m/z 206 (M<sup>+</sup>); Anal. Calcd. for C<sub>11</sub>H<sub>11</sub>FN<sub>2</sub>O: C, 64.07; H, 5.38; N, 13.58. Found: C, 64.11; H, 5.47; N, 13.48.

**4d**: (44%). Oil; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.39 (1H, t, *J* 2.3), 3.16 (3H, s), 4.24 (2H, d, *J* 2.3), 5.38 (2H, br s, missing after deuteriation), 6.72 (1H, d, *J* 9.0), 8.08 (1H, dd, *J* 2.6, 9.0), 8.21 (1H, d, *J* 2.6); IR (nujol) 1620, 2110, 3260, 3390, 3490 cm<sup>-1</sup>; MS m/z 233 (M<sup>+</sup>); Anal. Calcd. for C<sub>11</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub>: C, 56.65; H, 4.75; N, 18.02. Found: C, 56.74; H, 4.91; N, 18.13.

General procedure for preparation of 5-methyl[1,2,3]triazolo[1,5-a][1,4]benzodiazepin-6(4H)-ones 6a-d. NaNO<sub>2</sub> (1.2 mmol) was added portionwise to a solution of 4a-d (0.6 mmol) in 1N aq HCl (4 mL) and glacial AcOH (7 mL) under stirring and cooling at 0 °C. After stirring for 40 min, the mixture was treated with cold Et<sub>2</sub>O (16 mL) and NaN<sub>3</sub> (3.5 mmol) was added portionwise under vigorous stirring and ice-cooling for 3 h. The organic layer was separated, washed with aq NaHCO<sub>3</sub> and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure to give 6a-d.

**6a**: (41%). M.p. 169-171 °C (diisopropyl ether); <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 3.21 (3H, s), 4.42 (2H, s), 7.55 (1H, ddd, *J* 1.2, 7.7, 7.8), 7.68 (1H, ddd, *J* 1.5, 7.6, 7.7), 7.74 (1H, s), 7.98 (1H, dd, *J* 1.2, 7.6), 8.07 (1H, dd, *J* 1.5, 7.8); <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ 36.56 (q), 42.15 (t), 122.92 (d), 127.65 (s), 129.48 (d), 131.01 (d), 132.65 (d), 133.02 (s), 133.22 (d), 134.73 (s), 166.72 (s); IR (nujol) 1645 cm<sup>-1</sup>; MS *m/z* 214 (35, M<sup>+</sup>), 186 (44), 185 (58), 143 (73), 115 (100%); Anal. Calcd. for C<sub>11</sub>H<sub>10</sub>N<sub>4</sub>O; C, 61.67; H, 4.71; N, 26.15. Found: C, 61.62; H, 4.84; N, 26.23.

**6b**: (55%). M.p. 146-148 °C (diisopropyl ether);  ${}^{1}$ H-NMR (CDCl<sub>3</sub>)  $\delta$  3.25 (3H, s), 4.47 (2H, s), 7.67 (1H, dd, J 2.4, 8.7), 7.77 (1H, s), 7.98 (1H, d, J 8.7), 8.09 (1H, d, J 2.4);  ${}^{13}$ C-NMR (CDCl<sub>3</sub>)  $\delta$  36.55 (q), 42.09 (t), 124.34 (d), 128.88 (s), 131.19 (d), 131.49 (s), 132.54 (d), 133.34 (d), 134.51 (s), 135.63 (s), 165.42 (s); IR (nujol) 1640 cm<sup>-1</sup>; MS m/z 250 (14,  $M^{+}$ +2) 248 (39,  $M^{+}$ ), 222 (17), 221 (38), 220 (52), 219 (100),178 (44), 177 (72), 151 (21), 149 (50), 114 (71%); Anal. Calcd. for  $C_{11}H_{9}ClN_{4}O$ ; C, 53.13; H, 3.65; N, 22.53. Found: C, 53.20; H, 3.58; N, 22.58.

**6c**: (43%). M.p. 155-156 °C (diisopropyl ether);  ${}^{1}$ H-NMR (CDCl<sub>3</sub>)  $\delta$  3.25 (3H, s), 4.47 (2H, s), 7.42 (1H, ddd, J 2.9, 7.3, 8.9), 7.77 (1H, s), 7.80 (1H, dd, J 2.9, 8.9), 8.02 (1H, dd, J 4.8, 8.9);  ${}^{13}$ C-NMR (CDCl<sub>3</sub>)  $\delta$  36.25 (q), 41.70 (t), 118.82 (d), 120.24 (d), 124.73 (d), 125.45 (s), 126.67 (s), 128.23 (s), 130.63 (d), 133.99

(s), 163.79 (s); IR (nujol) 1635 cm<sup>-1</sup>; MS m/z 232 (35, M<sup>+</sup>), 204 (44), 203 (100), 161 (55), 133 (94%); Anal. Calcd. for  $C_{11}H_9FN_4O$ ; C, 56.90; H, 3.91; N, 24.13. Found: C, 56.99; H, 4.03; N, 24.27.

**6d**: (47%). M.p. 197-198 °C (diisopropyl ether);  ${}^{1}$ H-NMR (CDCl<sub>3</sub>)  $\delta$  3.30 (3H, s). 4.54 (2H, s), 7.26 (1H, d, J 8.9), 7.83 (1H, s). 8.55 (1H, dd, J 2.6, 8.9), 9.00 (1H, d, J 2.6);  ${}^{13}$ C-NMR (CDCl<sub>3</sub>)  $\delta$  36.97 (q). 41.98 (t), 124.28 (d), 127.74 (d), 128.83 (d), 131.70 (d), 134.86 (s), 136.89 (s), 145.76 (s), 147.88 (s), 164.63 (s); IR (nujol) 1650 cm<sup>-1</sup>; MS m/z 259 (51, M<sup>+</sup>), 231 (100), 230 (86), 188 (91), 142 (62), 114 (35%); Anal. Calcd. for  $C_{11}H_9N_5O_3$ ; C, 50.97; H, 3.50; N, 27.02. Found: C, 50.88; H, 3.43; N, 27.17.

**8-Amino-5-methyl[1,2,3]triazolo[1,5-a][1,4]benzodiazepin-6(4***H***)-one 6e. A mixture of 10% Pd/C (100 mg) and <b>6d** (103 mg, 0.4 mmol) in MeOH (80 mL) and CHCl<sub>3</sub> (80 ml) was stirred under H<sub>2</sub> for 2 h. After filtration through celite, the solvent was evaporated under reduced pressure. The crude product was chromatographed on silica with chloroform/methanol 10:1 as eluent to give **6e** (89 mg, 98%). M.p. 190-192 °C (diisopropyl ether); <sup>1</sup>H-NMR (DMSO<sub>-d6</sub>)  $\delta$  3.06 (3H, s), 4.51 (2H, s), 5.76 (2H, br s, missing after deuteriation), 6.91 (1H, dd, J 2.4, 8.7), 7.06 (1H, d, J 2.4), 7.54 (1H, d, J 8.7), 7.83 (1H, s); IR (nujol) 1630, 3215, 3330 cm<sup>-1</sup>; MS m/z 229 (100, M<sup>+</sup>), 201 (47), 200 (69), 174 (20), 158 (43), 130 (30%); Anal. Calcd. for  $C_{11}H_{11}N_5O$ : C, 57.63; H, 4.84; N, 30.55. Found: C, 57.53; H, 4.91; N, 30.70.

Acknowledgements: We are grateful to MURST and CNR for financial support.

#### References

- 1. Vida, J.A. in Medicinal Chemistry, Wolf, M.W. and Burger, A. Eds; Wiley, New York, 1981, p. 787.
- 2. Landquist, J.K. in *Comprehensive Heterocylic Chemistry*, Katritzky, A.R. and Rees, C.W. Eds; Pergamon Press, Oxford, 1984, Vol. 1, Ch. 1/06.
- 3. Sharp, J.T. in *Comprehensive Heterocyclic Chemistry*, Katritzky, A.R. and Rees, C.W. Eds; Pergamon Press, Oxford, 1984, Vol. 7, Ch. 5/18.
- 4. Hester, J.B., Jr. in Antianxiety Agents, Berger, J.G. Ed.; Wiley, New York, 1986, pp. 51-126.
- 5. Fryer, R.I. in *Comprehensive Medicinal Chemistry*, Hansch, C. Ed; Pergamon Press, New York, 1990, Vol. 3, pp. 539-566.
- 6. The Merck Index, 12th edition, Budavari, S. Ed; Merck & Co., Whitehouse Station, New Jersey, 1996.
- 7. Fröstl, W.; Maître, L. Pharmacopsych. 1989, 22, 54.
- 8. Broggini, G.; Zecchi, G.; Molteni, G. Gazz. Chim. Ital. 1997, 127, 809.
- 9. Broggini, G.; Garanti, L.; Molteni, G.; Zecchi, G. J. Chem. Res. 1997, 380 (S), 2215 (M).
- 10. Coppola, G.M. Synthesis 1980, 505.
- 11. Rupe, H.; Kersten, L. Helv. Chim. Acta, 1926, 9, 578.